TL;DR
Researchers have discovered a novel small molecule, SKLB-11A, that potently activates SIRT3, a key enzyme for mitochondrial health. This activation occurs through a unique allosteric mechanism involving a conformational change in the Leu298 residue of SIRT3, leading to significant cardioprotective effects in both cellular and animal models of heart damage.
What Problem Does This Paper Address?
Sirtuin 3 (SIRT3) is a crucial mitochondrial enzyme that plays a vital role in maintaining cellular energy production and protecting against oxidative stress. Its dysregulation is implicated in various diseases, including heart conditions. While SIRT3 is a promising therapeutic target for cardioprotection, developing effective and selective small-molecule activators has been a significant challenge. Existing activators often lack specificity or their mechanisms of action are not fully understood, hindering the development of targeted therapies. This paper aims to address this gap by identifying a novel SIRT3 activator with a distinct binding mode and demonstrating its therapeutic potential for heart protection.
Methods
The study employed a multi-pronged approach combining computational and experimental techniques:
- Virtual Screening: A large chemical database (ChemDiv) was screened using Schrödinger's Glide software to identify potential SIRT3 binders. This involved high-throughput virtual screening (HTVS), standard precision (SP) docking, and ultra-high precision (XP) docking, followed by MMGBSA calculations to estimate binding free energy.
- In Vitro Assays:
- Fluor de Lys (FDL) assay: Used to measure SIRT3 deacetylation activity.
- Mass Spectrometry (MS)-based deacetylation assay: Confirmed direct SIRT3 activation.
- Cell Viability Assays (MTT): Assessed the protective effects of compounds in doxorubicin (Dox)-induced cardiotoxicity models using H9c2 cells.
- Surface Plasmon Resonance (SPR) and Biolayer Interferometry (BLI): Used to quantify the binding affinity and kinetics of SKLB-11A to SIRT3.
- Cellular Thermal Shift Assay (CETSA): Evaluated the thermal stability of SIRT3 in the presence of SKLB-11A, indicating direct binding.
- Western Blotting: Analyzed protein expression levels, including SIRT3, MnSOD, acetylated MnSOD, LC3, p62, PINK1, and Parkin.
- JC-1 Assay: Measured mitochondrial membrane potential.
- ATP Assay: Quantified cellular ATP content.
- In Vivo Models:
- Doxorubicin-induced cardiotoxicity model: Used in mice to evaluate the cardioprotective effects of SKLB-11A.
- Myocardial Ischemia/Reperfusion (I/R) injury model: Used in mice to assess SKLB-11A's efficacy in a different type of heart damage.
- Echocardiography: Assessed cardiac function (EF and FS) in animal models.
- Histological Analysis (H&E, Masson's trichrome): Evaluated tissue damage and fibrosis.
- Biochemical analysis (LDH, CK-MB, BNP): Measured markers of myocardial injury.
- Structural Biology: X-ray crystallography was used to determine the co-crystal structure of SIRT3 bound to SKLB-11A, revealing the binding mode and key interactions.
- Mutagenesis: Site-directed mutagenesis was employed to investigate the role of specific amino acids, particularly Leu298, in SKLB-11A binding and SIRT3 activation.
Datasets
The study utilized a large chemical database (ChemDiv) for virtual screening. For experimental validation, various cell lines (H9c2 cardiomyocytes) and animal models (mice, rats) were used. Specific datasets for protein structures (PDB ID: 3GLS, 8V2N) were used for structural analysis and docking.
Key Insights and Ideas
- Novel Allosteric Binding Site: SKLB-11A binds to SIRT3 at a unique allosteric site, distinct from the catalytic NAD+ binding pocket. This is a significant finding as it opens up new avenues for designing selective SIRT3 activators.
- Leu298 Conformational Flip: The binding of SKLB-11A induces a conformational change in the side chain of Leu298, which is crucial for its potent activation of SIRT3. This observation provides a mechanistic explanation for the allosteric activation.
- First-in-Class Distinct Binding Mode Activator: SKLB-11A is presented as the first small-molecule allosteric SIRT3 activator with a clearly defined, novel binding mode, offering a valuable tool for further research into SIRT3 biology.
- Autophagy/Mitophagy Induction: SKLB-11A's cardioprotective effects are mediated, in part, by promoting autophagy and mitophagy, critical cellular processes for clearing damaged mitochondria and maintaining cellular health.
- Broad Therapeutic Potential: The compound demonstrates efficacy in two distinct models of cardiac injury (doxorubicin-induced cardiotoxicity and ischemia/reperfusion injury), suggesting its potential for treating a range of heart conditions.
Key Results
- SKLB-11A exhibits submicromolar affinity and high efficacy for SIRT3 activation.
- In vitro, SKLB-11A significantly enhanced SIRT3 deacetylation activity with an EC50 of 21.95 ± 1.57 µM.
- SKLB-11A protected H9c2 cells from doxorubicin-induced toxicity, increasing cell viability to 78.88 ± 0.65% compared to control.
- In vivo, SKLB-11A treatment significantly improved cardiac function (EF and FS) in both doxorubicin-induced cardiotoxicity and I/R injury mouse models.
- SKLB-11A reduced serum markers of myocardial injury (LDH, CK-MB, BNP) and infarct size in animal models.
- The compound demonstrated favorable pharmacokinetic properties in rats.
- Structural analysis revealed a novel binding mode involving interactions with His248 and Val292, and a conformational flip of Leu298.
- SKLB-11A showed high selectivity for SIRT3 over other sirtuin isoforms (SIRT1, SIRT2, SIRT5, SIRT6).
Limitations and Future Work
- Limited understanding of precise interaction patterns: While structural analysis revealed a novel binding mode, further detailed mechanistic studies could elucidate the precise interactions and allosteric effects more comprehensively.
- Further exploration of therapeutic applications: While promising in preclinical models, further studies are needed to explore the long-term efficacy, safety, and optimal dosing for various cardiovascular conditions in more complex models and eventually in clinical trials.
- Investigating off-target effects: Although selectivity for SIRT3 was demonstrated, comprehensive profiling for potential off-target effects in various biological systems would be beneficial for drug development.
- Optimization of drug-like properties: While SKLB-11A shows acceptable pharmacokinetic properties, further optimization could potentially enhance its bioavailability and therapeutic index.
The authors suggest that SKLB-11A, as a first-in-class allosteric activator with a distinct binding mode, holds significant promise for the development of targeted cardioprotective therapies and serves as a valuable tool for exploring the physiological and pathological roles of SIRT3.
Summary updated